申请人:ATEA Pharmaceuticals, Inc.
                            
                            
                                公开号:EP3865136A1
                            
                            
                                公开(公告)日:2021-08-18
                            
                            
The use of described compounds or pharmaceutically acceptable salts or compositions thereof for the treatment of a host infected with an RNA virus other than HCV, or other disorder more fully described herein.
                            将所述化合物或其药学上可接受的盐或组合物用于治疗感染了除 HCV 以外的 RNA 病毒的宿主或本文更全面描述的其他疾病。